CADTH Reimbursement Review - Upadacitinib (Rinvoq) - Sponsor: AbbVie Corporation Therapeutic area: Ankylosing spondylitis

Canadian Agency for Drugs and Technologies in Health

Share artifact

Or copy link:

Register Login

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Accessing this content requires a membership

Check your affiliation Start a trial

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Add to list

You have no lists yet

Manage lists

Citation

Health, C., 2023. CADTH Reimbursement Review - Upadacitinib (Rinvoq) - Sponsor: AbbVie Corporation Therapeutic area: Ankylosing spondylitis, Canadian Agency for Drugs and Technologies in Health. Canada. Retrieved from https://canadacommons.ca/artifacts/4817032/cadth-reimbursement-review-upadacitinib-rinvoq-sponsor/5653675/ on 04 May 2024. CID: 20.500.12592/swq366.

Download citation (RIS)

Full-page Screenshot

Screenshot of https://coherent-commons.s3.amazonaws.com/artifacts/file/file/14f5937c-1024-49fb-91dd-d8cf328d4239.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIA23B6R4NTCRHS5NZ3%2F20240504%2Fus-east-2%2Fs3%2Faws4_request&X-Amz-Date=20240504T142914Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=30c9f9d9e04adfc94b1d55a923cd74e5b66429f55f2b5f1153cae5f547c649b5

CADTH Reimbursement Review - Upadacitinib (Rinvoq) - Sponsor: AbbVie Corporation Therapeutic area: Ankylosing spondylitis

Authors

Tables

Share artifact

Add to list

Citation

Full-page Screenshot